Trexquant Investment LP Grows Position in Celcuity, Inc. $CELC

Key Points

• Trexquant Investment LP increased its stake in Celcuity, Inc. by 131.3% during the 1st quarter, bringing their total shares to 26,920, valued at approximately $272,000.
• Celcuity's stock has seen significant price adjustments, with analysts raising the price target to an average of $56.50 and several firms, including Leerink Partners and HC Wainwright, issuing "buy" ratings.
• Insider trading activity includes Director David Dalvey selling 100,000 shares for nearly $4.4 million, reducing his holdings in the company by 44.44%.

Trexquant Investment LP boosted its stake in shares of Celcuity, Inc. (NASDAQ:CELC - Free Report) by 131.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,920 shares of the company's stock after buying an additional 15,280 shares during the period. Trexquant Investment LP owned approximately 0.07% of Celcuity worth $272,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EntryPoint Capital LLC increased its holdings in shares of Celcuity by 18.4% in the 1st quarter. EntryPoint Capital LLC now owns 24,687 shares of the company's stock worth $250,000 after purchasing an additional 3,840 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Celcuity by 35.1% in the 1st quarter. Wellington Management Group LLP now owns 84,825 shares of the company's stock worth $858,000 after purchasing an additional 22,049 shares in the last quarter. Nuveen LLC bought a new stake in shares of Celcuity in the 1st quarter worth $704,000. Gagnon Securities LLC increased its holdings in shares of Celcuity by 3.5% in the 1st quarter. Gagnon Securities LLC now owns 54,310 shares of the company's stock worth $549,000 after purchasing an additional 1,831 shares in the last quarter. Finally, Perkins Capital Management Inc. bought a new stake in shares of Celcuity in the 1st quarter worth $115,000. Institutional investors own 63.33% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on CELC shares. Leerink Partners lifted their target price on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a report on Monday, July 28th. HC Wainwright lifted their target price on Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Needham & Company LLC reduced their target price on Celcuity from $74.00 to $70.00 and set a "buy" rating for the company in a report on Friday, August 15th. Finally, Stifel Nicolaus assumed coverage on Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 target price for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $56.50.

Celcuity Stock Performance

Shares of CELC stock traded up $0.16 on Monday, reaching $55.07. The stock had a trading volume of 1,522,135 shares, compared to its average volume of 839,896. The stock has a market cap of $2.34 billion, a P/E ratio of -15.96 and a beta of 0.72. Celcuity, Inc. has a 1 year low of $7.57 and a 1 year high of $63.06. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The company has a 50 day simple moving average of $39.65 and a 200 day simple moving average of $20.90.

Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.14). Equities research analysts expect that Celcuity, Inc. will post -2.62 EPS for the current year.

Insiders Place Their Bets

In related news, Director David Dalvey sold 100,000 shares of Celcuity stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the transaction, the director directly owned 125,000 shares in the company, valued at approximately $5,497,500. The trade was a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.78% of the company's stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.